Navigation Links
Endo Pharmaceuticals to Acquire Indevus Pharmaceuticals
Date:1/5/2009

s transaction represents a unique opportunity for us to achieve these goals. The combined company will market nine products through three specialty sales forces and have the capability to develop innovative new therapies using a novel drug delivery technology. We believe this will make Endo a stronger competitor, a more valuable health care supplier and a more successful company."

Indevus chairman and chief executive officer, Glenn L. Cooper, M.D., stated, "This transaction allows us to capture significant value for our shareholders and create new value for patients, physicians and shareholders of both companies under Endo's leadership. We believe Endo's proven commercial capabilities, targeted approach to medical marketing and unique understanding of the changes taking place in health care delivery today will ensure the success of our current and future products. We welcome and fully support this acquisition."

Endo expects that the transaction will be dilutive to the company's earnings in 2009 and is targeted to become accretive to Endo's earnings in 2010. Endo expects to achieve up to $40 million in cost savings and will provide more complete financial guidance during its fourth quarter and full-year earnings conference call in February.

Novel Products and Drug-Delivery Technology

Endo currently markets proprietary and generic products for the treatment and management of pain. Indevus currently markets products to treat overactive bladder, prostate cancer and central precocious puberty and is pursuing regulatory approval of drugs to treat hypogonadism and bladder cancer.

Mr. Holveck noted, "In addition to the very successful drug, VANTAS(R), we are particularly excited about the opportunity to add three innovative drug therapies, SUPPRELIN(R) LA, NEBIDO(R) and octreotide implant, to our product portfolio. All three are intended to address significant patient needs in
'/>"/>

SOURCE Endo Pharmaceuticals
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine news :

1. Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference
2. Schering-Plough/Merck Pharmaceuticals Announce FDA Filing Acceptance of New Drug Application for Loratadine/Montelukast Tablet
3. Provectus Pharmaceuticals, Inc. Begins Phase 2 Clinical Trial for Metastatic Melanoma
4. Idenix Pharmaceuticals to Present at Two Upcoming Investor Conferences
5. Vista Partners Updates Coverage on Tapestry Pharmaceuticals
6. Transcept Pharmaceuticals, Inc. to Present at UBS 2007 Global Life Sciences Conference
7. Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on Tapestry Pharmaceuticals, Inc.
8. Amylin Pharmaceuticals to Webcast Corporate Overview During 43rd Annual Meeting of the European Association for the Study of Diabetes
9. Major Pharma Clinical Case Studies From Amgen, AstraZeneca, GSK, Intermune, Cephalon Inc, Sunesis Pharmaceuticals and Dartmouth Medical School During Fall Clinical Focused Programs
10. Provectus Pharmaceuticals, Inc. releases summary results of phase 1 metastatic melanoma study
11. Class Settlement Could Result in Considerable Savings for Certain Consumers of Prescription Pharmaceuticals
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/23/2014)... DC (PRWEB) July 23, 2014 ... for ATA 2015, ATA’s twentieth annual meeting and ... The meeting, expected to attract over 5,000 attendees ... will take place May 3-5, 2015, in Los ... most renowned healthcare technology professionals from researchers, clinicians, ...
(Date:7/23/2014)... ( FXS ) is a genetic disorder that causes ... autistic spectrum, as well as cognitive deficits. It is ... the most common cause of autism. , Now biomedical ... a study that sheds light on the ... (July 23) in the Journal of Neuroscience , ...
(Date:7/23/2014)... Olympic gold medal-winning speed skater Chad Hedrick ... July 18. Hedrick visited Roanoke as the special guest ... Olympic-style event celebrating its 25th Anniversary in 2014. Foot ... sponsor of the Commonwealth Games, which like Foot Levelers ... all activity levels. , Hedrick, a native of Houston, ...
(Date:7/23/2014)... Amy Norton HealthDay ... The timing of a girl,s first menstrual period may be ... new study suggests. Researchers have identified over 100 ... menarche -- a woman,s first menstrual period. The researchers hope ... number of diseases ranging from type 2 diabetes to breast ...
(Date:7/23/2014)... 2014 Texas Physical Therapy Specialists (TexPTS) ... their Westlake, Westgate, Liberty Hill, Parmer, Balcones, and Georgetown ... of Orthopaedic Certified Specialist (OCS) or ... PT, DPT, OCS, Tony Lauretta, PT, DPT, OCS, Jason ... Joseph Leech, PT, DPT, OCS, and Mary Grimberg, PT, ...
Breaking Medicine News(10 mins):Health News:ATA Seeks Speakers to Present at the World’s Largest Telemedicine, mHealth and Telehealth Conference 2Health News:Study links enzyme to autistic behaviors 2Health News:Study links enzyme to autistic behaviors 3Health News:US Olympian Chad Hedrick Visits Foot Levelers 2Health News:Gene Study Gives New Insight Into Puberty in Girls 2Health News:Gene Study Gives New Insight Into Puberty in Girls 3Health News:Texas Physical Therapy Specialists Congratulates New Board Certified Specialists 2Health News:Texas Physical Therapy Specialists Congratulates New Board Certified Specialists 3
... the millions of Americans whose vision is slowly ebbing due ... cell may be riding to the rescue. ,In ... fetal stem cells have been shown to protect the vision ... of diseases that afflict humans. The new study appears today ...
... Diabetes and high blood pressure, two conditions rooted in ... than race alone in determining// who is mostly likely ... from cardiologists at Johns Hopkins. Each year, nearly 300,000 ... ,Experts say that racial disparities have long been known ...
... be a decade or more before science is available to ... way the agency approves knockoffs of traditional drugs. ... benefit companies such as Amgen Inc. and Genentech Inc, which ... products, some of the most complex and expensive on the ...
... LEXINGTON, Ky. − When studying a new blood thinner, one ... a slight increase in minor bleeding—nose bleeds and bruising,// an ... the leading cause of heart attack and stroke. While potentially ... bleeding in some patients, requiring frequent monitoring of blood levels. ...
... ancient parasitic disease causing tennis-ball-size ulcers so painful that ... in less than two years// become the second illness ... water treatment and other preventive methods, the United Nations ... the culmination of years of effort by local and ...
... Hewitt, the health secretary said that computer based therapy ... and anxiety//. This will be available to all patients ... Fear fighter and Beating the blues have been designed ... health experts have warned that computer aided programs may ...
Cached Medicine News:Health News:Stem Cell Therapy Shows Promise for Rescuing Deteriorating Vision 2Health News:Stem Cell Therapy Shows Promise for Rescuing Deteriorating Vision 3Health News:Who Gets Heart Failure? Race Takes Back Seat to Diabetes and High Blood Pressure 2Health News:Who Gets Heart Failure? Race Takes Back Seat to Diabetes and High Blood Pressure 3Health News:FDA Cites Challenges of Generic Biotech 2Health News:New Blood Thinner May Work Without Bleeding Risk 2Health News:Ancient Worm Disease Could Be Eradicated Within Two Years, UN Agency Reports 2Health News:Computer Based Therapy For Depression 2
(Date:7/23/2014)...  The management team at Columbia Laboratories, Inc. ... conference call on July 31, 2014, to discuss ... 30, 2014.  The call details are as follows:Date: ... EDTDial-in numbers: , Toll free: (877) 870-4263 (U.S.), ... archive): , www.columbialabs.com , under ,Investor, or ...
(Date:7/23/2014)... July 23, 2014 Global healthcare ... is facing currency headwinds, increased price competition and supply ... Andrew Witty points out that the company is ... as reason to be confident about long-term prospects as ... growth. CFO Simon Dingemans adds ...
(Date:7/23/2014)... DUBLIN , July 23, 2014 ... addition of the "Prepackaged Medical Kits and ... to their offering. ... worldwide markets for Prepackaged Medical Kits and Trays ... ENT Custom Trays, Ophthalmic Custom Trays, Custom Basin ...
Breaking Medicine Technology:Columbia Laboratories to Discuss Second Quarter 2014 Financial Results on July 31st Conference Call 2Prepackaged Medical Kits and Trays - Global Strategic Business Report: Updated 2014 Report 2
... 20 Today, Family Research,Council President Tony Perkins ... Shinya Yamanaka. Thomson, the first to grow human ... in the journals Science,and Cell, respectively, showing that ... human skin cells, without first creating or,destroying human ...
... International,Corporation (Nasdaq: PRXL ), a ... Dr. Victor Kiri, formerly with GlaxoSmithKline,as ... Clinical Research,Services business. Dr. Kiri,s responsibilities ... conduct of comparative observational studies, offering,epidemiological ...
Cached Medicine Technology:PAREXEL Expands Late Phase Clinical Research Services and Appoints Leading Pharmacoepidemiology Expert Victor Kiri 2PAREXEL Expands Late Phase Clinical Research Services and Appoints Leading Pharmacoepidemiology Expert Victor Kiri 3PAREXEL Expands Late Phase Clinical Research Services and Appoints Leading Pharmacoepidemiology Expert Victor Kiri 4
Monitorr ICP external CSF drainage system with self-contained ICP setting....
... Sophysa external neurological drainage system combines ... all the essential functions for CSF ... technological solutions contribute to make this ... is available as a single item ...
... for neuro and skull base surgery. ... craniofacial surgery, pediatric neurosurgery, bony defects ... skull base regions, neuro trauma. Dedicated ... implants in one compact kit. MRI ...
14 cm - 5 1/2, 6.0 mm , for drill handles and hand drills....
Medicine Products: